Patent Rights – Diabetic Biomarker

Please see the patent rights for THE INVENTION EP 2626704B1 (local copy).

Procalcitonin Kit and Diagnostic Device Producers and Diagnostic Companies.

Procalcitonin test users or Public –Private Medical Institutions.

If you see any suspicious patent infringement of EP 2626704B1 please send an e-mail or direct contact with the patent owner Dr. Mehmet Ali SOYLEMEZ All patent violators will face to patent infringement sue.

All procalcitonin kit producers and users must see claims of Patented Invention EP 2626704B1.

Claims

Procalcitonin immunoassay for in vitro diagnosis of a patient having pancreatic diabetes mellitus and/or diabetic foot syndrome, comprising: determining the level of procalcitonin in a sample selected from the group consisting of a blood sample, a serum sample and a plasma sample obtained from the patient with blood leucocyte counts within normal value ranges of 4000 to 10000 leucocytes per mm3 and comparing the level of procalcitonin to a threshold level, whereby, when the level of procalcitonin exceeds said threshold level, the patient is diagnosed with pancreatic diabetes mellitus and/or diabetic foot syndrome, and wherein said threshold level is 0.03 ± 0.002 ng/ml.

Diabetic Foot Syndrome (DFS) as defined by the World Health Organization (WHO), is an ”ulceration of the foot (distally from the ankle and including the ankle) associated with NEUROPATHY and different grades of ISCHEMIA and INFECTION”.

Please see, other Claims and Descriptions.

All procalcitonin kit users (PUBLIC OR PRIVATE MEDICAL INSTITUTIONS OR DIAGNOSTIC COMPANIES etc.) must be aware of this patent rights. Manifested-Diabetes Mellitus and DİABETİC FOOT SYNDROME patients must ask patent rights for procalcitonin before testing.

Patent rights for procalcitonin test for Non–Manifested Diabetic patients have B.R.A.H.M.S GmbH (ThermoFisher SCIENTIFIC) diagnostic company (EP 2293076B1).

My patent rights (EP 2626704B1) shares with B.R.A.H.M.S GmbH (ThermoFisher SCIENTIFIC) patent (EP 2293076B1), half and half; According to EUROPEAN PATENT OFFICE, APPEAL OF BOARD DECISION (T 2063/14 [Procalcitonin in Diabetes/B.R.A.H.M.S GmbH] of 28.11.2019…

PLEASE SEE PATENT VALIDATED COUNTRIES FOR THIS EUROPEAN PATENT. (EP 2626704B1)

This patent validated and active at list of countries.

EXAMPLE OF POSSIBLE OTHER BENEFITS THAT THE PARALLEL APPROACHED DIAGNOSTIC KITS TO BE CREATED UNDER THIS PATENT CAN PROVIDE TO DIABETIC PATIENTS

The risk of death due to CORONA VIRUS is 4-5 times higher in patients with DIABETIC OR DIABETIC FOOT SYNDROME AT THE CORONA VIRUS PANDEMIA. BUT THANKS TO THIS INVENTION AND WITH A PARALLEL APPROACH DIAGNOSIS; It is predicted that it will be significantly reduce the risk of death by enabling early diagnosis and treatment of DIABETIC AND / OR DIABETIC FOOT SYNDROME INFECTED WITH CORONA VIRUS.

FROM THE BIO-MARKERS IN THE REQUESTS (CLAIMS) AND DESCRIPTIONS (DEFINITION) OF THIS PATENT; C-REACTIVE PROTEIN (CRP) is used to determine the severity of CORONA VIRUS INFECTION in the early period, INTERLOKIN-6 (IL-6) as a diagnosis and treatment approach in cytokine storm. As a vascular marker, CREATINE KINASE (CK); in order to reveal the destruction of the body and muscles and tissues (including heart muscle) due to VIRUS, and ANGIOTENSIN-II could help to determine the risk of death due to ,CORONA VIRUS. SO, PROCALCITONIN (PCT) and MARKER COMBINATION COULD SIGNIFICANTLY INCREASE THE SURVIVAL POSSIBILITY OF CORONA PATIENTS .

IN THIS CASE, TOGETHER WITH PROCALCITONIN; BIO-MARKER COMBINATION SHOULD BE CHOSEN; INTERLOKIN-6 (IL-6), C-REACTIVE PROTEIN (CRP), CREATIN KINASE (CK) AND ANGIOTENSIN-II (2). THIS BIO-MARKER COMBINATION IS UNDER THE PROTECTION OF THIS PATENT. (PLEASE SEE;”EP 2 626 704 B1″ PATENT CLAIMS- (2), PATENT DESCRIPTION [0019], [0020] and [0022]. PLEASE SEE; EP 2 626 704 B1 PATENT CLAIMS-2 AND DESCRIPTIONS [0019], [0020], [0022] ).

[Reference; BIO-MARKERS ASSOCIATED WİTH COVID-19 DISEASE PROGRESSION. Crit.Rev.Clin.Lab.Sci.2020: 1-11

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284147/#__ffn_sectitle

AS Seen, THIS PATENT, DUE TO THE PARALLEL APPROACH DIAGNOSIS; IT CONTRIBUTES TO THE TREATMENT AND SURVIVAL OF PATIENTS WITH DIABETIC PATIENT OR DIABETIC FOOT SYNDROME WITH AN ADVANCED METHOD.

TURKISH TRANSLATION

BU PATENT KAPSAMINDA OLUŞTURULACAK PARELEL YAKLAŞIMLI TANI KİT’LERİNİN DİYABETİK HASTALARA SAĞLAYABİLECEĞİ OLASI DİĞER FAYDALARA İLİŞKİN ÖRNEKLEME

KORONA VİRÜS PANDEMİ’sinde DİYABETİK YADA DİYABETİK AYAK SENDROM’lu hastaların CORONA VİRÜS’e bağlı ölüm riskinin normale göre 4-5 kat daha fazla olması, Diyabetik hastaların hayatta kalma olasılığını azaltıyordu. ANCAK, BU BULUŞ SAYESİNDE VE PARELEL YAKLAŞIMLI TANI İLE; YALNIZCA: ŞEKER HASTALIĞI VEYA DİYABETİK AYAK SENDROMUN’da değil, aynı zaman da KORONA VİRÜS’le İNFEKTE DİYABETİK VE/VEYA DİYABETİK AYAK SENDROMLU HASTALARIN’ DA erken tanı ve tedavisinin takibine olanak sağlayarak, ölüm riskini önemli ölçüde azaltatacağı öngörülmektedir.

BU PATENTİN İSTEMLERİ (İDDİALAR) VE TARİFNAMESİNDE (TANIM) YER ALAN BİYO-MARKER ’LARDAN; PROKALSİTONİN;ŞEKER HASTALIĞI VEYA DİYABETİK AYAK SENDROMU’NUN TANISINDA VE TEDAVİSİNİN TAKİBİNDE; C-REAKTİF PROTEİN (CRP), erken dönemde KORONA VİRÜS İNFESİYONU’NUN ağırlık derecesini saptamada, İNTERLÖKİN-6 (IL-6) KORONA VİRÜS’e bağlı, sitokin fırtınasında tanı ve tedavi yaklaşımında, KREATİN KİNAZ(CK) vasküler marker olarak, KORONA VİRÜS’e bağlı vücutaki ve kas ve dokulardaki yıkımı(kalp kası dahil) ortaya koymak için, ANJİOTENSİN-II, ise KORONA VİRÜS’e bağlı ölüm riskini belirlemek için, PROKALSİTONİN(PCT) ile birlikte marker kombinasyonun’da PARELEL YAKLAŞIMLI TANI VE TEDAVİDE YER ALIR; VE BÖYLECE, DİYABETİK VE/VEYA DİYABETİK AYAK SENDROMLU HASTALARIN HAYATTA KALMA OLASILIĞINI ÖNEMLİ ÖLÇÜDE ARTIRIR.

BU DURUMDA, KORONA VİRÜS İLE İNFEKTE, ŞEKER HASTASI YADA DİYABETİK AYAK SENDROMLU HASTALARIN TANI VE TEDAVİSİNİN TAKİBİNDE: PROKALSİTONİN İLE BİRLİKTE; İNTERLÖKİN-6 (IL-6), C-REAKTİF PROTEİN (CRP), KREATİN KİNAZ (CK) VE ANJİOTENSİN-II(2) BİYO- MARKER KOMBİNASYONU SEÇİLMELİDİR. BU BİYO-MARKER KOMBİNASYONU’DA ‘EP 2 626 704 B1’ PATENT’İN KORUMASI ALTINDA’dır. (LÜTFEN BAKINIZ;PATENT İDDİALAR-(2), PATENT TARİFNAMESİ [0019], [0020] ve [0022]. PLEASE SEE; EP 2 626 704 B1 PATENT CLAİMS-2 AND DESCRIPTIONS [0019], [0020], [0022] ).

[Referans; BIO-MARKERS ASSOCIATED WİTH COVİD-19 DISEASE PROGRESSION. Crit.Rev.Clin.Lab.Sci.2020:1-11. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284147/#__ffn_sectitle

GÖRÜLDÜĞÜ GİBİ BU PATENT, PARELEL YAKLAŞIMLI TANI SAYESİNDE DE; ŞEKER HASTASI YADA DİYABETİK AYAK SENDROMLU HASTALARIN, TEDAVİSİNDE VE HAYATTA KALIMIN DA GELİŞMİŞ BİR YÖNTEMLE KATKI SAĞLAMAKTADIR.

*All patent violators will face legal action.